OR WAIT null SECS
Buffers, stabilizers, and cryoprotectants play major roles in cell therapy formulations.
The success of mRNA-based vaccines paves the way for mRNA in oncology and beyond.
The authors give an overview of scaling approaches and present good scaling practices for the biopharma industry.
March 29, 2024
J&J’s nipocalimab is in development for reducing the risk of FNAIT in alloimmunized pregnant adults, a rare disease that may risk the life of the fetus or newborn.
March 28, 2024
AstraZeneca notes that Ultomiris is the first and only long-acting C5 complement inhibitor that offers NMOSD patients the potential to live without relapsing.
March 27, 2024
AbbVie’s acquisition of Landos includes a lead asset that boosts its portfolio in autoimmune and inflammatory diseases, while the ADC, ELAHERE, gets full FDA approval.
March 25, 2024
Webinar Date/Time: Thu, Thu, Apr 18, 2024 11:00 AM EDT
Webinar Date/Time: Thu, Apr 25, 2024 11:00 AM EDT
March 21, 2024
Webinar Date/Time: Wed, May 8, 2024 11:00 AM EDT
March 15, 2024
ProBioGen and Mapp Biopharmaceutical will use the former’s GlymaxX technology to develop a cell line for an afucosylated antibody that targets Marburg virus infection
March 13, 2024
Under a new agreement, Chime Biologics will manufacture Domain Therapeutics’ antibody cancer immunotherapy candidate, DT-7012.
March 08, 2024
EMA has validated two MAAs submitted by AstraZeneca and Daiichi Sankyo for datopotamab deruxtecan in two types of cancer.
March 07, 2024
Johnson & Johnson’s $2 billion acquisition of Ambrx boosts its pipeline of next-generation ADCs for cancer treatment.